Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05744219

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Led by Jon Unosson · Updated on 2024-10-21

338

Participants Needed

1

Research Sites

186 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of the study is to investigate if iv iron formulation improve recovery after surgery with blood loss. Post-operative anaemia is a common debilitating condition after major surgery due to a combination of preoperative iron deficiency anaemia (IDA) and per-operative blood loss. Median blood loss following hepatopancreatobiliary (HPB) and complex aortic surgery typically range between 500-1000 ml. Bioavailability of iron may be a rate limiting factor in erythropoiesis in anaemia secondary to blood loss. For the IRIS trial, it is hypothesized that intravenously (iv) administered Ferric Carboxymaltose after a per-operative blood loss of 400-4000 ml, improves post-operative recovery and reduces the RBC transfusion. Patients scheduled for elective HPB surgery or complex aortic surgery will be screened for eligibility and recruited into the study. By the end of the surgical procedure, if blood loss is estimated to 400-4000 ml, the patient is randomized 1:1 to iv 1000 mg Ferric Carboxymaltose or placebo. The primary endpoint is a composite of death, number of RBC transfusions, post-operative severe anemia (Hb \<80 g/L) and FACT-An Quality of life (QoL) five weeks after surgery, assessed by win ratio. The trial will also examine effects on; a) levels of Hb; b) markers of erythropoiesis and iron bioavailability; c) post-operative complications; d) post-operative recovery; e) performance status; f) subgroups based on type of surgery and degree of anemia and iron deficiency; g) re-admissions; h) long term outcome based on patient medical records and i) how post-operative recovery differs between those with low (\<400 ml), high (400-4000 ml) and very high (\>4000 ml) per-operative blood loss. Recruitment will continue until 338 patients are randomized or 304 have completed the five week follow up The coordinating center of the trial is the Department of Surgery at Uppsala University Hospital. Participating sites are also Linköping University Hospital and Lund University Hospital, all in Sweden. Other sites may be added.

CONDITIONS

Official Title

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provision of written informed consent
  • Male and female patients
  • Weight > 50 kg
  • 18 years of age or older
  • Scheduled for complex aortic surgery, liver resection, or pancreatic resection
Not Eligible

You will not qualify if you...

  • Expected survival less than six months
  • Intravenous iron therapy within one month prior to surgery
  • Severe anemia with hemoglobin less than 80 mg/L before surgery
  • Contraindication to Ferric Carboxymaltose
  • Iron overloading disorder such as hemochromatosis
  • Risk of small future liver remnant size
  • Pre-operative renal replacement therapy
  • Enrolled in another drug or medical device study within 30 days prior to this study
  • Another planned major surgery before the five-week follow-up
  • Unsuitable for inclusion according to the investigator
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Uppsala University Hospital

Uppsala, Sverige, Sweden

Actively Recruiting

Loading map...

Research Team

J

Jon Unosson, MDPhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here